Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study

Overview

To collect and analyze data on females with hemophilia so as to better define the difference between the study population and the male population with hemophilia.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: January 2010

Detailed Description

This study is designed as an epidemiological study with retrospective clinical and genetic data collection and prospective quality of life (QOL) data collections and genotyping of subjects without current molecular diagnosis. Data on the genetic/chromosomal etiology of the condition will be collected through chart review. For those subjects who have not had molecular or cytogenetic analysis, molecular and cytogenetic testing will be offered after genetic counseling. Those subjects who agree to have genetic testing will have 5-10 ml of blood drawn and sent to the cytogenetic laboratory at Weill Cornell Medical College for testing to determine the chromosomal complement, and 5 ml of blood sent to Dr. Arupa Ganguly at the University of Pennsylvania for the identification of a factor VIII or factor IX mutation, and X-chromosome inactivation studies.

Arms, Groups and Cohorts

  • Females with Hemophilia
    • Females with severe or moderate Hemophilia A or B.

Clinical Trial Outcome Measures

Primary Measures

  • The prevalence of females with severe or moderate hemophilia A or B in the United States.
    • Time Frame: Study Duration

Secondary Measures

  • Collect existing data on the genetic and/or chromosomal causes for severe and moderate hemophilia A and B in females in the United States.
    • Time Frame: Study Duration
  • To determine the natural history of hemophilia in females by collecting and analyzing data on the symptoms, treatment patterns, and complications of hemophilia in this cohort.
    • Time Frame: Study Duration
  • Collect and analyze data on the health-related quality of life and psychosocial adaptation to disease of females in the United States.
    • Time Frame: Study Duration

Participating in This Clinical Trial

Inclusion Criteria

  • Females with severe (FVIII<0.01u/dl) or moderate (FVIII-0.01<0.06 u/dl) hemophilia A – Females with severe (FIX<0.01u/dl) or moderate (FIX-0.01<0.06u/dl) hemophilia B – Willingness to participate in the study. Exclusion Criteria:

  • Subjects who do not meet the inclusion criteria with respect to gender or hemophilia severity.

Gender Eligibility: Female

Minimum Age: 1 Month

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Weill Medical College of Cornell University
  • Collaborator
    • CSL Behring
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • William B Mitchell, MD, Principal Investigator, Weill Medical College of Cornell University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.